Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy

Wu, Jianmin; Wang, Shan; Zheng, Bo; Qiu, Xinyao; Wang, Hongyang; Chen, Lei

doi:10.3389/fimmu.2021.669150

Cited by 35 publications

(37 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken all, more ongoing clinical trials incorporating modulation of microbiota via FMT in cancer therapies are now in their infant stage, though several clinical tests have exhibited m u c h e x c i t e m e n t ( N C T 0 4 1 3 0 7 6 3 , N C T 0 4 0 5 6 0 2 6 , NCT03341143, etc.) (83).…”

Section: Challenges Clinical Application and Possible Strategies Of G...mentioning

confidence: 99%

Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy

Zhou

Chen

2022

Front. Oncol.

View full text Add to dashboard Cite

In the past few decades, immunotherapy has emerged as one of the most promising strategies among current treatments of cancer. In particular, the field of PD1/PD-L1 inhibitors has been boosted, widely applied into clinical practice with potent therapeutic efficacy and remarkable survival benefits on various cancers such as melanoma, non-small cell lung cancer (NSCLC), and urothelial carcinoma (UC). However, the application of PD1/PD-L1 blockade therapy is still quite restricted because of unexpected toxicities, limited response rate, as well as associated resistance. In consequence, searching for potential strategies that possibly resolve the existing limitations and enhance the therapeutic responsiveness of PD1/PD-L1 blockade is of great significance. Fortunately, the gut microbiome has been demonstrated to serve as a pivotal regulator in anti-PD1/PD-L1 therapy, providing an applicable tool to improve anti-PD1/PD-L1 clinical efficacy. In this review, we summarized published advancements about how microbiota modulated in anti-PD1/PD-L1 therapy and illustrated its underlying mechanisms, giving insights into putative manipulation of gut microbiota to facilitate PD1/PD-L1 blockade.

show abstract

Section: Challenges Clinical Application and Possible Strategies Of G...mentioning

confidence: 99%

Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy

Zhou

Chen

2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…These findings support the notion that KD could impact the expression of ICs on tumor cells and/or that on T cells and, consequently, the responsiveness to ICIs. The composition of the gut microbiota was known to impact the efficacy of ICIs [ 76 , 77 ]. Remarkably, the KD has been shown to increase the relative gut microbiota abundance of Akkermansia muciniphila [ 78 ], a bacterium capable of ameliorating therapeutic responses to ICIs.…”

Section: Diet and Response To Icismentioning

confidence: 99%

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors

Zhang

et al. 2022

Life

View full text Add to dashboard Cite

Immunotherapy has revolutionized the established therapeutics against tumors. As the major immunotherapy approach, immune checkpoint inhibitors (ICIs) achieved remarkable success in the treatment of malignancies. However, the clinical gains are far from universal and durable, because of the primary and secondary resistance of tumors to the therapy, or side effects induced by ICIs. There is an urgent need to find safe combinatorial strategies that enhance the response of ICIs for tumor treatment. Diets have an excellent safety profile and have been shown to play pleiotropic roles in tumor prevention, growth, invasion, and metastasis. Accumulating evidence suggests that dietary regimens bolster not only the tolerability but also the efficacy of tumor immunotherapy. In this review, we discussed the mechanisms by which tumor cells evade immune surveillance, focusing on describing the intrinsic and extrinsic mechanisms of resistance to ICIs. We also summarized the impacts of different diets and/or nutrients on the response to ICIs therapy. Combinatory treatments of ICIs therapy with optimized diet regimens own great potential to enhance the efficacy and durable response of ICIs against tumors, which should be routinely considered in clinical settings.

show abstract

“…Discovering the role of gut microbiota leads to new therapeutical targets [ 140 ]. A fecal microbiota transplant (FMT) was developed in order to modulate gut microbiota and enhance the response rate and/or ameliorate toxicity.…”

Section: The Microbiome: the New Eden?mentioning

confidence: 99%

Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review

et al. 2022

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICI) have revolutionized the management of locally advanced and advanced non-small lung cancer (NSCLC). With an improvement in the overall survival (OS) as both first- and second-line treatments, ICIs, and especially programmed-death 1 (PD-1) and programmed-death ligands 1 (PD-L1), changed the landscape of thoracic oncology. The PD-L1 level of expression is commonly accepted as the most used biomarker, with both prognostic and predictive values. However, even in a low expression level of PD-L1, response rates remain significant while a significant number of patients will experience hyperprogression or adverse events. The dentification of such subtypes is thus of paramount importance. While several studies focused mainly on the prediction of the PD-L1 expression status, others aimed directly at the development of prediction/prognostic models. The response to ICIs depends on a complex physiopathological cascade, intricating multiple mechanisms from the molecular to the macroscopic level. With the high-throughput extraction of features, omics approaches aim for the most comprehensive assessment of each patient. In this article, we will review the place of the different biomarkers (clinical, biological, genomics, transcriptomics, proteomics and radiomics), their clinical implementation and discuss the most recent trends projecting on the future steps in prediction modeling in NSCLC patients treated with ICI.

show abstract

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy

Cited by 35 publications

References 90 publications

Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy

Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors

Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review

Contact Info

Product

Resources

About